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Introduction. Pulmonary Langerhans cell granulomatosis is a rare disease with a variable course. In pulmonary Langerhans cell
granulomatosis pulmonary hypertension is frequent and has an independent prognostic impact. A vasculopathy which ist not
related to ventilatory disturbance and ﬁbrosis has been identiﬁed. An arteriopathy and even a venulopathy have been described.
Due to this possible venulopathy vasodilators carry a signiﬁcant risk for pulmonary congestion and edema. No drugs have
been approved until now. Case Presentation. One female with PLCG developed severe PH four years after primary diagnosis of
pulmonary Langerhans cell granulomatosis. Retrospective analysis of lung biopsies revealed an arterial vasculopathy at the time
of primary diagnosis without clinical signs of PH at this time. Sildenaﬁl led to a sustained improvement of hemodynamic features
and exercise capacity. Conclusion. This paper underlines that patients with PLCG with an arterial vasculopathy-related PH might
improve under sildenaﬁl. Further trials addressing treatment of PH and vasculopathy are needed.
1.Introduction
The course of adult pulmonary Langerhans cell granulo-
matosis (PLCG) is variable: in 25% the disease is sponta-
neously regressive, in 50% it remains stable, and in 25%
there is a severe disease progression [1, 2]. In severe PLCG
pulmonary hypertension (PH) is a common complication.
In patients waiting for lung transplantation PH was found in
90% [3].
CrausmanandKeoghshowedthatinpatientswithsevere
PLCG abnormalities of ventilatory function are common but
not exercise-limiting. The impairment of exercise capacity is
due to pulmonary vascular dysfunction [4, 5].
PH is often severe and not related to the ventilatory dis-
order or hypoxemia [3, 6, 7]. Diﬀerent forms of a pulmonary
vasculopathy aﬀecting pulmonary arteries and pulmonary
veins are described [6]. A progression of the vasculopathy in
patients with no change of histopathological ﬁndings of lung
parenchyma and a stable ventilatory disorder was reported
[6]. The pathogenesis of this vasculopathy remains unclear:
cytokines and growth factors may play an important role
[8, 9].
Modern vasoactive drugs that are approved for pul-
monary arterial hypertension (PAH) seem to be an attractive
tool for treating PH caused by a pulmonary vasculopathy in
PLCG, but data of randomized controlled trials are missing.
A single experience of Bosentan was reported [10].
Side eﬀects of a vasoactive therapy leading to pulmonary
edema might be a possible complication in patients with a
predominant venous vasculopathy [6].
2. Case Presentation
We report successful treatment of PH with sildenaﬁl in a
female patient with adult PLCG.
A 51-year-old female was ﬁrst admitted to our PH out-
patient clinic in March 2010. In 2005 a PLCG was diagnosed
and proven by histopathological ﬁndings. In 2005 the patient
was treated with corticosteroids. In 2010 the patient reported
worsening of exercise tolerance and exertional dyspnea
over the last months. Echocardiography showed elevated
pulmonaryarterypressureanddilatedrightatriumandright
ventricle (Figure 1(a)). Pulmonary function test revealed2 Case Reports in Medicine
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Figure 1: (a) Pulmonary Langerhans cell granulomatosis echocardiography, 4-chamber view, before treatment with sildenaﬁl. (b) Pulmo-
nary Langerhans cell granulomatosis echocardiography, 4-chamber view, after treatment with sildenaﬁl.
Table 1: Pulmonary Langerhans cell granulomatosis: functional parameters before and under sildenaﬁl.
Parameter Before Sildenaﬁl 3 months after the start
of sildenaﬁl
6 months after the start
of sildenaﬁl
9 months after the start
of sildenaﬁl
6-MWD (m) 350 400 380 420
Exercise Capacity (W) 36 65 55 55
VE/VCO2 80 41 36 33
EQO2 AT 40 38 32 33
EQCO2 AT 52 42 36 38
nT-pro-BNP pg/mL 301 54 22 16
PO2 (mmHg) 68 65 68 78
pCO2 (mmHg) 31 31 34 34
SO2%9 4 9 4 9 4 9 6
TAPSE (mm) 18 19 18 24
Tei-Index 0,67 0,40 0,81 0,02
LVEI 1,22 1,0 1,0
mPAP (mmHg) 56 36 36 33
PVR dyn∗s∗cm−5 1035 500 496 338
PCWP (mmHg) 15 8 12 13
RAP (mmHg) 5 12 11 10
CI (l/min/m2) 2,0 2,7 2,8 2,6
moderate airﬂow obstruction and reduced transfer factor
forcarbon-monoxide(Figure 2).Thecomputedtomography
showed ﬁbrosis, cysts, and bronchiectasis but no active
lesions as noduli or ground glass opacities (Figure 3). We
performed an RHC and so conﬁrmed a severe precapillary
PH (Table 1). Under exercise conditions the patient showed
hypoxemia (Table 1). Retrospectively we analysed tissue
samples of the year 2005 in which the PLCG was diagnosed:
there were no clinical signs of PH, but tissue samples showed
signs of a pulmonary vasculopathy (Figures 4(a)–4(e)).
In March 2010 we ﬁrst started prednisolone with
0.5mg/kg. There was no eﬀect on exercise capacity, lung
function, oxygen partial pressure, radiological ﬁndings, or
pulmonary artery pressure. After the start of sildenaﬁl
(20mg three times a day) dramatic hemodynamic and
clinical improvements were seen. Table 1 shows the results
from RHC, 6-minute walking test, cardiopulmonary exercise
testing, and echocardiography before and after initiation
of sildenaﬁl. Oxygen tension remained stable, and no
pulmonary congestion was seen. In the following 12 monthsCase Reports in Medicine 3
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Figure 2: Pulmonary Langerhans cell granulomatosis, pulmonary function test.
the patient remained stable, a rehabilitation was initiated,
and listing for lung transplantation was considered.
3. Discussion
Not surprisingly there was no eﬀect of a second course of
corticosteroids in 2010 because CT scans showed endstage
pulmonary Langerhans’ cell granulomatosis with bronchiec-
tasis and ﬁbrosis without signs of activity as nodules.
The noted improvement under sildenaﬁl is attributed
to an eﬀect on a pulmonary vasculopathy [6]. Surprisingly
histopathologicalfeaturesofavasculopathyhadbeenalready
found in our patient 5 years ago, when she presented the
ﬁrst time with pulmonary Langerhans cell granulomatosis
but without clinical signs of PH. As mentioned above
foregoing studies reported arterial and venous vasculopa-
thy. So a treatment with pulmonary vasodilators inﬂu-
encing the arterial vasculopathy was taken into account.
On the other hand in patients with predominant venous
vasculopathy side eﬀects as pulmonary congestion caused
by a vasodilatation of pulmonary arteries might appear
a n dj u s th a v eb e e nd e s c r i b e d[ 6]. Such side eﬀects did
not appear under treatment with sildenaﬁl in the patient
reported here because the patient had a predominant arterial
vasculopathy. Gas exchange was stable, and therapy was
save.4 Case Reports in Medicine
(a) (b)
Figure 3: Pulmonary Langerhans cell granulomatosis, computed tomography.
(a) (b) (c)
(d) (e)
Figure 4: (a–e) Pulmonary Langerhans cell granulomatosis, pulmonary vessels, histological ﬁndings in 2005. (a, b) HE: H¨ amatoxylin-Eosin
stain, (c) MG: Masson-Goldner-stain, and (d, e) EVG: Elastica van Gieson stain.
The ventilatory disturbance and ﬁbrosis and the under-
lying PLCG are not inﬂuenced by sildenaﬁl, so that it is
not surprising that the patient did not experience complete
normalization of exercise capacity. For further management
a rehabilitation was initiated and listing for lung transplan-
tation was planned.
4. Conclusion
In PLCG and severe PH sildenaﬁl is a promising option and
should be considered for bridging to lung transplantation.
Sildenaﬁlshouldnotbeuseduncriticallyandpatientsshould
becontrolledcarefully,because,underspecialcircumstances,
especially a predominant pulmonary venous vasculopathy
side eﬀects as pulmonary edema might appear.
PH due to PLCG belongs to group 5 of the Dana Point
classiﬁcation, no drugs are approved for this kind of PH.
There is a need for further studies addressing treatment of
PH and vasculopathy.
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